Related Experiment Video
Updated: Nov 19, 2025

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
TMEM59 protects against cerebral ischemic stroke by suppressing pyroptosis and microglial activation
Liang Zhang1, Tao Wang2, Xiao-Fang Chen2
1Department of Anesthesiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511447, China.
Abstract:
Ischemic stroke is a common disease worldwide with high mortality and disability rates. Nevertheless, pathogenesis of ischemic stroke is still vague, and finding novel therapeutic target is urgently necessary. TMEM59 (also known as dendritic cell-derived factor 1, DCF1), a type I transmembrane protein, contains a minimal 19-amino-acid peptide in its intracellular domain, and has been involved in neurological pathology. However, its biological impacts on ischemic stroke are still unknown. In this study, we provided new evidence that TMEM59 expression was significantly down-regulated upon ischemia/reperfusion (I/R). The effect of stroke insult on TMEM59 expression change was only detected in microglial cells by in vitro studies. We observed that TMEM59 knockout markedly accelerated cerebral I/R in mice induced by middle cerebral artery occlusion (MCAO), as evidenced by the elevated infarction volume, neurological deficit scores, brain water contents and neuronal death, further contributing to the abnormal behaviors for mice. We then found that microglial activation reflected by the enhanced expression of Iba-1 was dramatically potentiated by TMEM59 knockout in MCAO-treated mice. Pyroptosis was highly triggered in mice with cerebral I/R, while being further aggravated in mice with TMEM59 deletion, as proved by the considerably increased expression of NLRP3, ASC, cleaved Caspase-1, GSDMD-N, mature-IL-1β and mature-IL-18. Additionally, TMEM59 knockout mice exhibited accelerated activation of NF-κB signaling pathway compared with the wild type group of mice after MCAO operation, indicating the anabatic neuroinflammation. The effects of TMEM59 suppression on ischemic stroke were confirmed in microglial cells with exposure to oxygen-glucose deprivation/reoxygenation (OGD/R). In contrast, the in vitro studies verified that improving TMEM59 expression effectively hindered pyroptosis and inflammation in microglial cells upon OGD/R treatment. Taken together, these findings illustrated protective effects of TMEM59 against ischemic stroke through restraining pyroptosis and inflammatory response.
Insights
TMEM59 protein is down-regulated in ischemic stroke. Its absence worsens stroke outcomes by increasing microglial activation, pyroptosis, and neuroinflammation, suggesting TMEM59 is protective.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Ischemic stroke presents significant global mortality and disability challenges.
- Understanding ischemic stroke pathogenesis and identifying therapeutic targets remain critical.
- The role of TMEM59 (dendritic cell-derived factor 1, DCF1) in ischemic stroke is currently unknown.
Purpose of the Study:
- To investigate the biological impact of TMEM59 on ischemic stroke.
- To elucidate the mechanism by which TMEM59 influences stroke pathology, particularly in microglial cells.
Main Methods:
- Utilized middle cerebral artery occlusion (MCAO) model in TMEM59 knockout and wild-type mice.
- Assessed cerebral infarction, neurological deficits, brain water content, and neuronal death.
- Analyzed microglial activation (Iba-1), pyroptosis markers (NLRP3, ASC, Caspase-1, GSDMD-N, IL-1β, IL-18), and NF-κB signaling.
- Conducted in vitro studies using microglial cells subjected to oxygen-glucose deprivation/reoxygenation (OGD/R).
Main Results:
- TMEM59 expression was significantly down-regulated in ischemia/reperfusion (I/R) models, primarily in microglial cells.
- TMEM59 knockout exacerbated cerebral I/R injury, increasing infarction volume, neurological deficits, and neuronal death.
- TMEM59 deficiency potentiated microglial activation and aggravated pyroptosis and neuroinflammation via NF-κB pathway activation.
- In vitro, TMEM59 suppression worsened OGD/R-induced pyroptosis and inflammation in microglial cells.
Conclusions:
- TMEM59 plays a protective role in ischemic stroke.
- TMEM59 restrains microglial activation, pyroptosis, and neuroinflammation following ischemic injury.
- TMEM59 represents a potential therapeutic target for mitigating ischemic stroke damage.

